Apidel receives grant of Japanese patent

Apidel received notice that the Japanese Patent Application No. 208-507201, entitled “Polylactide Compositions and Uses Thereof” has been granted.
Apidel holds several patents protecting both its ApidCOR™ and ApidSOL™ drug delivery polymer compounds for various regions.


Apidel appoints Business Development Associate

Apidel is pleased to announce the appointment of Vitalia Mitrovic as our Business Development Associate. Vitalia will be based at Apidel's offices at 29 Quai du Mont Blanc, Geneva and will be responsible for local, regional and international grant funding, as well as dealing with investor communication and relations.


Apidel's technology is the subject of a peer reviewed publication

A new paper with the title "Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways" has been published in the "Journal of Controlled Release".
The drug delivery system used in the study was based on Apidel’s proprietary ApidSOL™ technology. (http://www.ncbi.nlm.nih.gov/pubmed/25278258)


Apidel amongst the TOP100 startups in Switzerland!

“Each year, "startup.ch" launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung. From over 100,000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts.


Apidel's technology is the subject of a peer reviewed publication

A recent article published in the journal "Molecular Pharmaceutics" has described a study reporting enhanced delivery of tacrolimus into skin tissue using polymeric micelles as a delivery vehicle.
The drug delivery system used in the study was based on Apidel’s proprietary ApidSOL™ technology.(http://www.ncbi.nlm.nih.gov/pubmed/25057896)


Apidel appoints Alliance Manager

On March 1st, 2014, Apidel has announced the appointment of Victoria Sarraf as its Alliance Manager. Victoria will be based at Apidel's offices at 29 Quai du Mont Blanc, Geneva. Tel: +41 (0)22 731 2180.


Apidel receives grant of US patent

On January 17th, 2014, Apidel received notice from the United States Patent Office that its patent application US 13/778,038 would be granted. Together with the previously granted US 11/912,102, Apidel now has granted US patents protecting both its ApidCOR™ and ApidSOL™ drug delivery polymer compounds. Prosecution of applications in US, Canada, Europe, and Japan continues for the Apidel polymers and other aspects of Apidel's proprietary drug delivery technologies.


Apidel increases facility space, adds new employee

On October 21st, 2013, Apidel has announced an increase to its laboratory and office spaces, located in the Geneva area. The company has established a new headquarters office at Quai du Mont Blanc in Geneva, to add to its existing technical facilities in Plan-les-Ouates, within the life science incubator, Eclosion. In parallel, Apidel has increased its fulltime workforce, adding three positions in R&D and business development to manage Apidel's expanding drug delivery project portfolio.


US Patent granted

US patent 8,466,133 "Polylactide Compositions and Uses Thereof" granted by the United States' Patent Office !
This patent protects the polymer compositions in Apidel's ApidSol and ApidCor technologies which offer versatile solutions to a range of drug delivery challenges.\nApidel's technology enables our partners to optimize product design and maximize the therapeutic potential of their active compounds.

Apidel has an exclusive license to US 8,466,133 and other patent applications protecting its core drug delivery technologies.

Examination of Apidel's licensed patent portfolio is ongoing in other jurisdictions.


4th feasibility agreement

Apidel signs with one of the largest companies in the world for a new ophthalmic drug product using our ApidSOL™ technology.